{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "3d143d8c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 5 × 18</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Generic.Name</th><th scope=col>Trade.Name</th><th scope=col>Date.Designated</th><th scope=col>Orphan.Designation</th><th scope=col>Orphan.Designation.Status</th><th scope=col>FDA.Orphan.Approval.Status</th><th scope=col>Approved.Labeled.Indication</th><th scope=col>Marketing.Approval.Date</th><th scope=col>Exclusivity.End.Date</th><th scope=col>Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.</th><th scope=col>Sponsor.Company</th><th scope=col>Sponsor.Address.1</th><th scope=col>Sponsor.Address.2</th><th scope=col>Sponsor.City</th><th scope=col>Sponsor.State</th><th scope=col>Sponsor.Zip</th><th scope=col>Sponsor.Country</th><th scope=col>CF.Grid.Key</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;lgl&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Designated/Approved</td><td>NA</td><td>Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  </td><td>11/20/2001</td><td>11/20/2008</td><td>                                                                                                                                                                                                                                                                 </td><td>Actelion Pharmaceuticals Ltd        </td><td>1840 Gateway Drive      </td><td>Suite 300            </td><td>Cherry Hill </td><td>New Jersey</td><td>8002 </td><td>United States</td><td>134200</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Designated/Approved</td><td>NA</td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              </td><td>9/05/17   </td><td>9/05/24   </td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability</td><td>Actelion Pharmaceuticals Ltd        </td><td>1840 Gateway Drive      </td><td>Suite 300            </td><td>Cherry Hill </td><td>New Jersey</td><td>8002 </td><td>United States</td><td>134200</td></tr>\n",
       "\t<tr><th scope=row>3</th><td>(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19</td><td>Kymriah (tisagenlecleucel)</td><td>01/31/2014</td><td>For the treatment of Acute Lymphoblastic Leukemia                                            </td><td>Designated/Approved</td><td>NA</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          </td><td>08/30/2017</td><td>08/30/2024</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            </td><td>Novartis Pharmaceuticals Corporation</td><td>One Health Plaza,       </td><td>Bldg 315 - Room 3650B</td><td>East Hanover</td><td>New Jersey</td><td>7936 </td><td>United States</td><td>415113</td></tr>\n",
       "\t<tr><th scope=row>4</th><td>5-aminolevulinic acid                                                                                                               </td><td>Gleolan                   </td><td>01/15/2013</td><td>Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)</td><td>Designated/Approved</td><td>NA</td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  </td><td>6/06/17   </td><td>6/06/24   </td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    </td><td>NX Development Corporation          </td><td>1827 South Bayshore Lane</td><td>                     </td><td>Miami       </td><td>Florida   </td><td>33133</td><td>United States</td><td>387312</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>abatacept                                                                                                                           </td><td>Orencia                   </td><td>12/26/2017</td><td>Prevention of graft versus host disease                                                      </td><td>Designated/Approved</td><td>NA</td><td>prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor</td><td>12/15/2021</td><td>          </td><td>                                                                                                                                                                                                                                                                 </td><td>Bristol-Myers Squibb Co.            </td><td>P. O. Box 5326          </td><td>                     </td><td>Princeton   </td><td>New Jersey</td><td>8543 </td><td>United States</td><td>614117</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 5 × 18\n",
       "\\begin{tabular}{r|llllllllllllllllll}\n",
       "  & Generic.Name & Trade.Name & Date.Designated & Orphan.Designation & Orphan.Designation.Status & FDA.Orphan.Approval.Status & Approved.Labeled.Indication & Marketing.Approval.Date & Exclusivity.End.Date & Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. & Sponsor.Company & Sponsor.Address.1 & Sponsor.Address.2 & Sponsor.City & Sponsor.State & Sponsor.Zip & Sponsor.Country & CF.Grid.Key\\\\\n",
       "  & <chr> & <chr> & <chr> & <chr> & <chr> & <lgl> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <int>\\\\\n",
       "\\hline\n",
       "\t1 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Designated/Approved & NA & Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   & 11/20/2001 & 11/20/2008 &                                                                                                                                                                                                                                                                   & Actelion Pharmaceuticals Ltd         & 1840 Gateway Drive       & Suite 300             & Cherry Hill  & New Jersey & 8002  & United States & 134200\\\\\n",
       "\t2 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Designated/Approved & NA & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               & 9/05/17    & 9/05/24    & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability & Actelion Pharmaceuticals Ltd         & 1840 Gateway Drive       & Suite 300             & Cherry Hill  & New Jersey & 8002  & United States & 134200\\\\\n",
       "\t3 & (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 & Kymriah (tisagenlecleucel) & 01/31/2014 & For the treatment of Acute Lymphoblastic Leukemia                                             & Designated/Approved & NA & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           & 08/30/2017 & 08/30/2024 & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             & Novartis Pharmaceuticals Corporation & One Health Plaza,        & Bldg 315 - Room 3650B & East Hanover & New Jersey & 7936  & United States & 415113\\\\\n",
       "\t4 & 5-aminolevulinic acid                                                                                                                & Gleolan                    & 01/15/2013 & Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) & Designated/Approved & NA & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   & 6/06/17    & 6/06/24    & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     & NX Development Corporation           & 1827 South Bayshore Lane &                       & Miami        & Florida    & 33133 & United States & 387312\\\\\n",
       "\t5 & abatacept                                                                                                                            & Orencia                    & 12/26/2017 & Prevention of graft versus host disease                                                       & Designated/Approved & NA & prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor & 12/15/2021 &            &                                                                                                                                                                                                                                                                   & Bristol-Myers Squibb Co.             & P. O. Box 5326           &                       & Princeton    & New Jersey & 8543  & United States & 614117\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 5 × 18\n",
       "\n",
       "| <!--/--> | Generic.Name &lt;chr&gt; | Trade.Name &lt;chr&gt; | Date.Designated &lt;chr&gt; | Orphan.Designation &lt;chr&gt; | Orphan.Designation.Status &lt;chr&gt; | FDA.Orphan.Approval.Status &lt;lgl&gt; | Approved.Labeled.Indication &lt;chr&gt; | Marketing.Approval.Date &lt;chr&gt; | Exclusivity.End.Date &lt;chr&gt; | Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. &lt;chr&gt; | Sponsor.Company &lt;chr&gt; | Sponsor.Address.1 &lt;chr&gt; | Sponsor.Address.2 &lt;chr&gt; | Sponsor.City &lt;chr&gt; | Sponsor.State &lt;chr&gt; | Sponsor.Zip &lt;chr&gt; | Sponsor.Country &lt;chr&gt; | CF.Grid.Key &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Designated/Approved | NA | Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   | 11/20/2001 | 11/20/2008 | <!----> | Actelion Pharmaceuticals Ltd         | 1840 Gateway Drive       | Suite 300             | Cherry Hill  | New Jersey | 8002  | United States | 134200 |\n",
       "| 2 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Designated/Approved | NA | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               | 9/05/17    | 9/05/24    | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability | Actelion Pharmaceuticals Ltd         | 1840 Gateway Drive       | Suite 300             | Cherry Hill  | New Jersey | 8002  | United States | 134200 |\n",
       "| 3 | (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 | Kymriah (tisagenlecleucel) | 01/31/2014 | For the treatment of Acute Lymphoblastic Leukemia                                             | Designated/Approved | NA | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           | 08/30/2017 | 08/30/2024 | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             | Novartis Pharmaceuticals Corporation | One Health Plaza,        | Bldg 315 - Room 3650B | East Hanover | New Jersey | 7936  | United States | 415113 |\n",
       "| 4 | 5-aminolevulinic acid                                                                                                                | Gleolan                    | 01/15/2013 | Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) | Designated/Approved | NA | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   | 6/06/17    | 6/06/24    | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     | NX Development Corporation           | 1827 South Bayshore Lane | <!----> | Miami        | Florida    | 33133 | United States | 387312 |\n",
       "| 5 | abatacept                                                                                                                            | Orencia                    | 12/26/2017 | Prevention of graft versus host disease                                                       | Designated/Approved | NA | prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor | 12/15/2021 | <!----> | <!----> | Bristol-Myers Squibb Co.             | P. O. Box 5326           | <!----> | Princeton    | New Jersey | 8543  | United States | 614117 |\n",
       "\n"
      ],
      "text/plain": [
       "  Generic.Name                                                                                                                        \n",
       "1 bosentan                                                                                                                            \n",
       "2 bosentan                                                                                                                            \n",
       "3 (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19\n",
       "4 5-aminolevulinic acid                                                                                                               \n",
       "5 abatacept                                                                                                                           \n",
       "  Trade.Name                 Date.Designated\n",
       "1 Tracleer                   10/06/00       \n",
       "2 Tracleer                   10/06/00       \n",
       "3 Kymriah (tisagenlecleucel) 01/31/2014     \n",
       "4 Gleolan                    01/15/2013     \n",
       "5 Orencia                    12/26/2017     \n",
       "  Orphan.Designation                                                                           \n",
       "1 Treatment of pulmonary arterial hypertension                                                 \n",
       "2 Treatment of pulmonary arterial hypertension                                                 \n",
       "3 For the treatment of Acute Lymphoblastic Leukemia                                            \n",
       "4 Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)\n",
       "5 Prevention of graft versus host disease                                                      \n",
       "  Orphan.Designation.Status FDA.Orphan.Approval.Status\n",
       "1 Designated/Approved       NA                        \n",
       "2 Designated/Approved       NA                        \n",
       "3 Designated/Approved       NA                        \n",
       "4 Designated/Approved       NA                        \n",
       "5 Designated/Approved       NA                        \n",
       "  Approved.Labeled.Indication                                                                                                                                                                                                                                                                    \n",
       "1 Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              \n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  \n",
       "5 prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor\n",
       "  Marketing.Approval.Date Exclusivity.End.Date\n",
       "1 11/20/2001              11/20/2008          \n",
       "2 9/05/17                 9/05/24             \n",
       "3 08/30/2017              08/30/2024          \n",
       "4 6/06/17                 6/06/24             \n",
       "5 12/15/2021                                  \n",
       "  Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.                                                                                                                                                                       \n",
       "1                                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability\n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    \n",
       "5                                                                                                                                                                                                                                                                  \n",
       "  Sponsor.Company                      Sponsor.Address.1       \n",
       "1 Actelion Pharmaceuticals Ltd         1840 Gateway Drive      \n",
       "2 Actelion Pharmaceuticals Ltd         1840 Gateway Drive      \n",
       "3 Novartis Pharmaceuticals Corporation One Health Plaza,       \n",
       "4 NX Development Corporation           1827 South Bayshore Lane\n",
       "5 Bristol-Myers Squibb Co.             P. O. Box 5326          \n",
       "  Sponsor.Address.2     Sponsor.City Sponsor.State Sponsor.Zip Sponsor.Country\n",
       "1 Suite 300             Cherry Hill  New Jersey    8002        United States  \n",
       "2 Suite 300             Cherry Hill  New Jersey    8002        United States  \n",
       "3 Bldg 315 - Room 3650B East Hanover New Jersey    7936        United States  \n",
       "4                       Miami        Florida       33133       United States  \n",
       "5                       Princeton    New Jersey    8543        United States  \n",
       "  CF.Grid.Key\n",
       "1 134200     \n",
       "2 134200     \n",
       "3 415113     \n",
       "4 387312     \n",
       "5 614117     "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#.csv file needs to be saved only as comma-separated values type so it'll be read as a dataframe \n",
    "#Not .csv UTF-8 type, which will be read as list\n",
    "\n",
    "#Read .csv file\n",
    "df <- read.csv(\"Rare_diseases.csv\", sep = \",\", header = TRUE)\n",
    "\n",
    "#Show first 5 rows of the dataframe\n",
    "head(df, 5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "9826f40f",
   "metadata": {},
   "outputs": [],
   "source": [
    "#Change column name of Generic.Name by using index\n",
    "colnames(df)[1] <- c(\"Generic Name\")\n",
    "\n",
    "#Change column names using old column names\n",
    "colnames(df)[which(names(df) == \"Trade.Name\")] <- \"Trade Name\"\n",
    "colnames(df)[which(names(df) == \"Date.Designated\")] <- \"Date Designated\"\n",
    "colnames(df)[which(names(df) == \"Orphan.Designation\")] <- \"Orphan Designation\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "a8be19f5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 5 × 18</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Generic Name</th><th scope=col>Trade Name</th><th scope=col>Date Designated</th><th scope=col>Orphan Designation</th><th scope=col>Orphan.Designation.Status</th><th scope=col>FDA.Orphan.Approval.Status</th><th scope=col>Approved.Labeled.Indication</th><th scope=col>Marketing.Approval.Date</th><th scope=col>Exclusivity.End.Date</th><th scope=col>Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.</th><th scope=col>Sponsor.Company</th><th scope=col>Sponsor.Address.1</th><th scope=col>Sponsor.Address.2</th><th scope=col>Sponsor.City</th><th scope=col>Sponsor.State</th><th scope=col>Sponsor.Zip</th><th scope=col>Sponsor.Country</th><th scope=col>CF.Grid.Key</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;lgl&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Designated/Approved</td><td>NA</td><td>Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  </td><td>11/20/2001</td><td>11/20/2008</td><td>                                                                                                                                                                                                                                                                 </td><td>Actelion Pharmaceuticals Ltd        </td><td>1840 Gateway Drive      </td><td>Suite 300            </td><td>Cherry Hill </td><td>New Jersey</td><td>8002 </td><td>United States</td><td>134200</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Designated/Approved</td><td>NA</td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              </td><td>9/05/17   </td><td>9/05/24   </td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability</td><td>Actelion Pharmaceuticals Ltd        </td><td>1840 Gateway Drive      </td><td>Suite 300            </td><td>Cherry Hill </td><td>New Jersey</td><td>8002 </td><td>United States</td><td>134200</td></tr>\n",
       "\t<tr><th scope=row>3</th><td>(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19</td><td>Kymriah (tisagenlecleucel)</td><td>01/31/2014</td><td>For the treatment of Acute Lymphoblastic Leukemia                                            </td><td>Designated/Approved</td><td>NA</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          </td><td>08/30/2017</td><td>08/30/2024</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            </td><td>Novartis Pharmaceuticals Corporation</td><td>One Health Plaza,       </td><td>Bldg 315 - Room 3650B</td><td>East Hanover</td><td>New Jersey</td><td>7936 </td><td>United States</td><td>415113</td></tr>\n",
       "\t<tr><th scope=row>4</th><td>5-aminolevulinic acid                                                                                                               </td><td>Gleolan                   </td><td>01/15/2013</td><td>Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)</td><td>Designated/Approved</td><td>NA</td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  </td><td>6/06/17   </td><td>6/06/24   </td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    </td><td>NX Development Corporation          </td><td>1827 South Bayshore Lane</td><td>                     </td><td>Miami       </td><td>Florida   </td><td>33133</td><td>United States</td><td>387312</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>abatacept                                                                                                                           </td><td>Orencia                   </td><td>12/26/2017</td><td>Prevention of graft versus host disease                                                      </td><td>Designated/Approved</td><td>NA</td><td>prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor</td><td>12/15/2021</td><td>          </td><td>                                                                                                                                                                                                                                                                 </td><td>Bristol-Myers Squibb Co.            </td><td>P. O. Box 5326          </td><td>                     </td><td>Princeton   </td><td>New Jersey</td><td>8543 </td><td>United States</td><td>614117</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 5 × 18\n",
       "\\begin{tabular}{r|llllllllllllllllll}\n",
       "  & Generic Name & Trade Name & Date Designated & Orphan Designation & Orphan.Designation.Status & FDA.Orphan.Approval.Status & Approved.Labeled.Indication & Marketing.Approval.Date & Exclusivity.End.Date & Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. & Sponsor.Company & Sponsor.Address.1 & Sponsor.Address.2 & Sponsor.City & Sponsor.State & Sponsor.Zip & Sponsor.Country & CF.Grid.Key\\\\\n",
       "  & <chr> & <chr> & <chr> & <chr> & <chr> & <lgl> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <int>\\\\\n",
       "\\hline\n",
       "\t1 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Designated/Approved & NA & Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   & 11/20/2001 & 11/20/2008 &                                                                                                                                                                                                                                                                   & Actelion Pharmaceuticals Ltd         & 1840 Gateway Drive       & Suite 300             & Cherry Hill  & New Jersey & 8002  & United States & 134200\\\\\n",
       "\t2 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Designated/Approved & NA & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               & 9/05/17    & 9/05/24    & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability & Actelion Pharmaceuticals Ltd         & 1840 Gateway Drive       & Suite 300             & Cherry Hill  & New Jersey & 8002  & United States & 134200\\\\\n",
       "\t3 & (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 & Kymriah (tisagenlecleucel) & 01/31/2014 & For the treatment of Acute Lymphoblastic Leukemia                                             & Designated/Approved & NA & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           & 08/30/2017 & 08/30/2024 & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             & Novartis Pharmaceuticals Corporation & One Health Plaza,        & Bldg 315 - Room 3650B & East Hanover & New Jersey & 7936  & United States & 415113\\\\\n",
       "\t4 & 5-aminolevulinic acid                                                                                                                & Gleolan                    & 01/15/2013 & Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) & Designated/Approved & NA & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   & 6/06/17    & 6/06/24    & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     & NX Development Corporation           & 1827 South Bayshore Lane &                       & Miami        & Florida    & 33133 & United States & 387312\\\\\n",
       "\t5 & abatacept                                                                                                                            & Orencia                    & 12/26/2017 & Prevention of graft versus host disease                                                       & Designated/Approved & NA & prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor & 12/15/2021 &            &                                                                                                                                                                                                                                                                   & Bristol-Myers Squibb Co.             & P. O. Box 5326           &                       & Princeton    & New Jersey & 8543  & United States & 614117\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 5 × 18\n",
       "\n",
       "| <!--/--> | Generic Name &lt;chr&gt; | Trade Name &lt;chr&gt; | Date Designated &lt;chr&gt; | Orphan Designation &lt;chr&gt; | Orphan.Designation.Status &lt;chr&gt; | FDA.Orphan.Approval.Status &lt;lgl&gt; | Approved.Labeled.Indication &lt;chr&gt; | Marketing.Approval.Date &lt;chr&gt; | Exclusivity.End.Date &lt;chr&gt; | Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. &lt;chr&gt; | Sponsor.Company &lt;chr&gt; | Sponsor.Address.1 &lt;chr&gt; | Sponsor.Address.2 &lt;chr&gt; | Sponsor.City &lt;chr&gt; | Sponsor.State &lt;chr&gt; | Sponsor.Zip &lt;chr&gt; | Sponsor.Country &lt;chr&gt; | CF.Grid.Key &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Designated/Approved | NA | Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   | 11/20/2001 | 11/20/2008 | <!----> | Actelion Pharmaceuticals Ltd         | 1840 Gateway Drive       | Suite 300             | Cherry Hill  | New Jersey | 8002  | United States | 134200 |\n",
       "| 2 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Designated/Approved | NA | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               | 9/05/17    | 9/05/24    | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability | Actelion Pharmaceuticals Ltd         | 1840 Gateway Drive       | Suite 300             | Cherry Hill  | New Jersey | 8002  | United States | 134200 |\n",
       "| 3 | (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 | Kymriah (tisagenlecleucel) | 01/31/2014 | For the treatment of Acute Lymphoblastic Leukemia                                             | Designated/Approved | NA | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           | 08/30/2017 | 08/30/2024 | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             | Novartis Pharmaceuticals Corporation | One Health Plaza,        | Bldg 315 - Room 3650B | East Hanover | New Jersey | 7936  | United States | 415113 |\n",
       "| 4 | 5-aminolevulinic acid                                                                                                                | Gleolan                    | 01/15/2013 | Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) | Designated/Approved | NA | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   | 6/06/17    | 6/06/24    | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     | NX Development Corporation           | 1827 South Bayshore Lane | <!----> | Miami        | Florida    | 33133 | United States | 387312 |\n",
       "| 5 | abatacept                                                                                                                            | Orencia                    | 12/26/2017 | Prevention of graft versus host disease                                                       | Designated/Approved | NA | prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor | 12/15/2021 | <!----> | <!----> | Bristol-Myers Squibb Co.             | P. O. Box 5326           | <!----> | Princeton    | New Jersey | 8543  | United States | 614117 |\n",
       "\n"
      ],
      "text/plain": [
       "  Generic Name                                                                                                                        \n",
       "1 bosentan                                                                                                                            \n",
       "2 bosentan                                                                                                                            \n",
       "3 (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19\n",
       "4 5-aminolevulinic acid                                                                                                               \n",
       "5 abatacept                                                                                                                           \n",
       "  Trade Name                 Date Designated\n",
       "1 Tracleer                   10/06/00       \n",
       "2 Tracleer                   10/06/00       \n",
       "3 Kymriah (tisagenlecleucel) 01/31/2014     \n",
       "4 Gleolan                    01/15/2013     \n",
       "5 Orencia                    12/26/2017     \n",
       "  Orphan Designation                                                                           \n",
       "1 Treatment of pulmonary arterial hypertension                                                 \n",
       "2 Treatment of pulmonary arterial hypertension                                                 \n",
       "3 For the treatment of Acute Lymphoblastic Leukemia                                            \n",
       "4 Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)\n",
       "5 Prevention of graft versus host disease                                                      \n",
       "  Orphan.Designation.Status FDA.Orphan.Approval.Status\n",
       "1 Designated/Approved       NA                        \n",
       "2 Designated/Approved       NA                        \n",
       "3 Designated/Approved       NA                        \n",
       "4 Designated/Approved       NA                        \n",
       "5 Designated/Approved       NA                        \n",
       "  Approved.Labeled.Indication                                                                                                                                                                                                                                                                    \n",
       "1 Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              \n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  \n",
       "5 prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor\n",
       "  Marketing.Approval.Date Exclusivity.End.Date\n",
       "1 11/20/2001              11/20/2008          \n",
       "2 9/05/17                 9/05/24             \n",
       "3 08/30/2017              08/30/2024          \n",
       "4 6/06/17                 6/06/24             \n",
       "5 12/15/2021                                  \n",
       "  Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.                                                                                                                                                                       \n",
       "1                                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability\n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    \n",
       "5                                                                                                                                                                                                                                                                  \n",
       "  Sponsor.Company                      Sponsor.Address.1       \n",
       "1 Actelion Pharmaceuticals Ltd         1840 Gateway Drive      \n",
       "2 Actelion Pharmaceuticals Ltd         1840 Gateway Drive      \n",
       "3 Novartis Pharmaceuticals Corporation One Health Plaza,       \n",
       "4 NX Development Corporation           1827 South Bayshore Lane\n",
       "5 Bristol-Myers Squibb Co.             P. O. Box 5326          \n",
       "  Sponsor.Address.2     Sponsor.City Sponsor.State Sponsor.Zip Sponsor.Country\n",
       "1 Suite 300             Cherry Hill  New Jersey    8002        United States  \n",
       "2 Suite 300             Cherry Hill  New Jersey    8002        United States  \n",
       "3 Bldg 315 - Room 3650B East Hanover New Jersey    7936        United States  \n",
       "4                       Miami        Florida       33133       United States  \n",
       "5                       Princeton    New Jersey    8543        United States  \n",
       "  CF.Grid.Key\n",
       "1 134200     \n",
       "2 134200     \n",
       "3 415113     \n",
       "4 387312     \n",
       "5 614117     "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "head(df,5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "ee9c7bec",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[1] TRUE\n",
      "[1] 18\n",
      "[1] 1058\n"
     ]
    }
   ],
   "source": [
    "#Check .csv file is read into a dataframe and check numbers of columns and rows in total\n",
    "print(is.data.frame(df))\n",
    "print(ncol(df))\n",
    "print(nrow(df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "5a0dedbc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 5 × 17</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Generic Name</th><th scope=col>Trade Name</th><th scope=col>Date Designated</th><th scope=col>Orphan Designation</th><th scope=col>Orphan.Designation.Status</th><th scope=col>Approved.Labeled.Indication</th><th scope=col>Marketing.Approval.Date</th><th scope=col>Exclusivity.End.Date</th><th scope=col>Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.</th><th scope=col>Sponsor.Company</th><th scope=col>Sponsor.Address.1</th><th scope=col>Sponsor.Address.2</th><th scope=col>Sponsor.City</th><th scope=col>Sponsor.State</th><th scope=col>Sponsor.Zip</th><th scope=col>Sponsor.Country</th><th scope=col>CF.Grid.Key</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Designated/Approved</td><td>Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  </td><td>11/20/2001</td><td>11/20/2008</td><td>                                                                                                                                                                                                                                                                 </td><td>Actelion Pharmaceuticals Ltd        </td><td>1840 Gateway Drive      </td><td>Suite 300            </td><td>Cherry Hill </td><td>New Jersey</td><td>8002 </td><td>United States</td><td>134200</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Designated/Approved</td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              </td><td>9/05/17   </td><td>9/05/24   </td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability</td><td>Actelion Pharmaceuticals Ltd        </td><td>1840 Gateway Drive      </td><td>Suite 300            </td><td>Cherry Hill </td><td>New Jersey</td><td>8002 </td><td>United States</td><td>134200</td></tr>\n",
       "\t<tr><th scope=row>3</th><td>(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19</td><td>Kymriah (tisagenlecleucel)</td><td>01/31/2014</td><td>For the treatment of Acute Lymphoblastic Leukemia                                            </td><td>Designated/Approved</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          </td><td>08/30/2017</td><td>08/30/2024</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            </td><td>Novartis Pharmaceuticals Corporation</td><td>One Health Plaza,       </td><td>Bldg 315 - Room 3650B</td><td>East Hanover</td><td>New Jersey</td><td>7936 </td><td>United States</td><td>415113</td></tr>\n",
       "\t<tr><th scope=row>4</th><td>5-aminolevulinic acid                                                                                                               </td><td>Gleolan                   </td><td>01/15/2013</td><td>Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)</td><td>Designated/Approved</td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  </td><td>6/06/17   </td><td>6/06/24   </td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    </td><td>NX Development Corporation          </td><td>1827 South Bayshore Lane</td><td>                     </td><td>Miami       </td><td>Florida   </td><td>33133</td><td>United States</td><td>387312</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>abatacept                                                                                                                           </td><td>Orencia                   </td><td>12/26/2017</td><td>Prevention of graft versus host disease                                                      </td><td>Designated/Approved</td><td>prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor</td><td>12/15/2021</td><td>          </td><td>                                                                                                                                                                                                                                                                 </td><td>Bristol-Myers Squibb Co.            </td><td>P. O. Box 5326          </td><td>                     </td><td>Princeton   </td><td>New Jersey</td><td>8543 </td><td>United States</td><td>614117</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 5 × 17\n",
       "\\begin{tabular}{r|lllllllllllllllll}\n",
       "  & Generic Name & Trade Name & Date Designated & Orphan Designation & Orphan.Designation.Status & Approved.Labeled.Indication & Marketing.Approval.Date & Exclusivity.End.Date & Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. & Sponsor.Company & Sponsor.Address.1 & Sponsor.Address.2 & Sponsor.City & Sponsor.State & Sponsor.Zip & Sponsor.Country & CF.Grid.Key\\\\\n",
       "  & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <int>\\\\\n",
       "\\hline\n",
       "\t1 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Designated/Approved & Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   & 11/20/2001 & 11/20/2008 &                                                                                                                                                                                                                                                                   & Actelion Pharmaceuticals Ltd         & 1840 Gateway Drive       & Suite 300             & Cherry Hill  & New Jersey & 8002  & United States & 134200\\\\\n",
       "\t2 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Designated/Approved & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               & 9/05/17    & 9/05/24    & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability & Actelion Pharmaceuticals Ltd         & 1840 Gateway Drive       & Suite 300             & Cherry Hill  & New Jersey & 8002  & United States & 134200\\\\\n",
       "\t3 & (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 & Kymriah (tisagenlecleucel) & 01/31/2014 & For the treatment of Acute Lymphoblastic Leukemia                                             & Designated/Approved & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           & 08/30/2017 & 08/30/2024 & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             & Novartis Pharmaceuticals Corporation & One Health Plaza,        & Bldg 315 - Room 3650B & East Hanover & New Jersey & 7936  & United States & 415113\\\\\n",
       "\t4 & 5-aminolevulinic acid                                                                                                                & Gleolan                    & 01/15/2013 & Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) & Designated/Approved & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   & 6/06/17    & 6/06/24    & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     & NX Development Corporation           & 1827 South Bayshore Lane &                       & Miami        & Florida    & 33133 & United States & 387312\\\\\n",
       "\t5 & abatacept                                                                                                                            & Orencia                    & 12/26/2017 & Prevention of graft versus host disease                                                       & Designated/Approved & prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor & 12/15/2021 &            &                                                                                                                                                                                                                                                                   & Bristol-Myers Squibb Co.             & P. O. Box 5326           &                       & Princeton    & New Jersey & 8543  & United States & 614117\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 5 × 17\n",
       "\n",
       "| <!--/--> | Generic Name &lt;chr&gt; | Trade Name &lt;chr&gt; | Date Designated &lt;chr&gt; | Orphan Designation &lt;chr&gt; | Orphan.Designation.Status &lt;chr&gt; | Approved.Labeled.Indication &lt;chr&gt; | Marketing.Approval.Date &lt;chr&gt; | Exclusivity.End.Date &lt;chr&gt; | Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. &lt;chr&gt; | Sponsor.Company &lt;chr&gt; | Sponsor.Address.1 &lt;chr&gt; | Sponsor.Address.2 &lt;chr&gt; | Sponsor.City &lt;chr&gt; | Sponsor.State &lt;chr&gt; | Sponsor.Zip &lt;chr&gt; | Sponsor.Country &lt;chr&gt; | CF.Grid.Key &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Designated/Approved | Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   | 11/20/2001 | 11/20/2008 | <!----> | Actelion Pharmaceuticals Ltd         | 1840 Gateway Drive       | Suite 300             | Cherry Hill  | New Jersey | 8002  | United States | 134200 |\n",
       "| 2 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Designated/Approved | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               | 9/05/17    | 9/05/24    | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability | Actelion Pharmaceuticals Ltd         | 1840 Gateway Drive       | Suite 300             | Cherry Hill  | New Jersey | 8002  | United States | 134200 |\n",
       "| 3 | (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 | Kymriah (tisagenlecleucel) | 01/31/2014 | For the treatment of Acute Lymphoblastic Leukemia                                             | Designated/Approved | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           | 08/30/2017 | 08/30/2024 | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             | Novartis Pharmaceuticals Corporation | One Health Plaza,        | Bldg 315 - Room 3650B | East Hanover | New Jersey | 7936  | United States | 415113 |\n",
       "| 4 | 5-aminolevulinic acid                                                                                                                | Gleolan                    | 01/15/2013 | Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) | Designated/Approved | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   | 6/06/17    | 6/06/24    | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     | NX Development Corporation           | 1827 South Bayshore Lane | <!----> | Miami        | Florida    | 33133 | United States | 387312 |\n",
       "| 5 | abatacept                                                                                                                            | Orencia                    | 12/26/2017 | Prevention of graft versus host disease                                                       | Designated/Approved | prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor | 12/15/2021 | <!----> | <!----> | Bristol-Myers Squibb Co.             | P. O. Box 5326           | <!----> | Princeton    | New Jersey | 8543  | United States | 614117 |\n",
       "\n"
      ],
      "text/plain": [
       "  Generic Name                                                                                                                        \n",
       "1 bosentan                                                                                                                            \n",
       "2 bosentan                                                                                                                            \n",
       "3 (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19\n",
       "4 5-aminolevulinic acid                                                                                                               \n",
       "5 abatacept                                                                                                                           \n",
       "  Trade Name                 Date Designated\n",
       "1 Tracleer                   10/06/00       \n",
       "2 Tracleer                   10/06/00       \n",
       "3 Kymriah (tisagenlecleucel) 01/31/2014     \n",
       "4 Gleolan                    01/15/2013     \n",
       "5 Orencia                    12/26/2017     \n",
       "  Orphan Designation                                                                           \n",
       "1 Treatment of pulmonary arterial hypertension                                                 \n",
       "2 Treatment of pulmonary arterial hypertension                                                 \n",
       "3 For the treatment of Acute Lymphoblastic Leukemia                                            \n",
       "4 Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)\n",
       "5 Prevention of graft versus host disease                                                      \n",
       "  Orphan.Designation.Status\n",
       "1 Designated/Approved      \n",
       "2 Designated/Approved      \n",
       "3 Designated/Approved      \n",
       "4 Designated/Approved      \n",
       "5 Designated/Approved      \n",
       "  Approved.Labeled.Indication                                                                                                                                                                                                                                                                    \n",
       "1 Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              \n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  \n",
       "5 prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor\n",
       "  Marketing.Approval.Date Exclusivity.End.Date\n",
       "1 11/20/2001              11/20/2008          \n",
       "2 9/05/17                 9/05/24             \n",
       "3 08/30/2017              08/30/2024          \n",
       "4 6/06/17                 6/06/24             \n",
       "5 12/15/2021                                  \n",
       "  Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.                                                                                                                                                                       \n",
       "1                                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability\n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    \n",
       "5                                                                                                                                                                                                                                                                  \n",
       "  Sponsor.Company                      Sponsor.Address.1       \n",
       "1 Actelion Pharmaceuticals Ltd         1840 Gateway Drive      \n",
       "2 Actelion Pharmaceuticals Ltd         1840 Gateway Drive      \n",
       "3 Novartis Pharmaceuticals Corporation One Health Plaza,       \n",
       "4 NX Development Corporation           1827 South Bayshore Lane\n",
       "5 Bristol-Myers Squibb Co.             P. O. Box 5326          \n",
       "  Sponsor.Address.2     Sponsor.City Sponsor.State Sponsor.Zip Sponsor.Country\n",
       "1 Suite 300             Cherry Hill  New Jersey    8002        United States  \n",
       "2 Suite 300             Cherry Hill  New Jersey    8002        United States  \n",
       "3 Bldg 315 - Room 3650B East Hanover New Jersey    7936        United States  \n",
       "4                       Miami        Florida       33133       United States  \n",
       "5                       Princeton    New Jersey    8543        United States  \n",
       "  CF.Grid.Key\n",
       "1 134200     \n",
       "2 134200     \n",
       "3 415113     \n",
       "4 387312     \n",
       "5 614117     "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Remove column FDA.Orphan.Approval.Status \n",
    "df <- subset(df, select = -c(FDA.Orphan.Approval.Status))\n",
    "head(df, 5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "715574c1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 5 × 11</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Generic Name</th><th scope=col>Trade Name</th><th scope=col>Date Designated</th><th scope=col>Orphan Designation</th><th scope=col>Approved.Labeled.Indication</th><th scope=col>Marketing.Approval.Date</th><th scope=col>Exclusivity.End.Date</th><th scope=col>Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.</th><th scope=col>Sponsor.Company</th><th scope=col>Sponsor.State</th><th scope=col>Sponsor.Country</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  </td><td>11/20/2001</td><td>11/20/2008</td><td>                                                                                                                                                                                                                                                                 </td><td>Actelion Pharmaceuticals Ltd        </td><td>New Jersey</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              </td><td>9/05/17   </td><td>9/05/24   </td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability</td><td>Actelion Pharmaceuticals Ltd        </td><td>New Jersey</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>3</th><td>(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19</td><td>Kymriah (tisagenlecleucel)</td><td>01/31/2014</td><td>For the treatment of Acute Lymphoblastic Leukemia                                            </td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          </td><td>08/30/2017</td><td>08/30/2024</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            </td><td>Novartis Pharmaceuticals Corporation</td><td>New Jersey</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>4</th><td>5-aminolevulinic acid                                                                                                               </td><td>Gleolan                   </td><td>01/15/2013</td><td>Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)</td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  </td><td>6/06/17   </td><td>6/06/24   </td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    </td><td>NX Development Corporation          </td><td>Florida   </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>abatacept                                                                                                                           </td><td>Orencia                   </td><td>12/26/2017</td><td>Prevention of graft versus host disease                                                      </td><td>prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor</td><td>12/15/2021</td><td>          </td><td>                                                                                                                                                                                                                                                                 </td><td>Bristol-Myers Squibb Co.            </td><td>New Jersey</td><td>United States</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 5 × 11\n",
       "\\begin{tabular}{r|lllllllllll}\n",
       "  & Generic Name & Trade Name & Date Designated & Orphan Designation & Approved.Labeled.Indication & Marketing.Approval.Date & Exclusivity.End.Date & Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. & Sponsor.Company & Sponsor.State & Sponsor.Country\\\\\n",
       "  & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t1 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   & 11/20/2001 & 11/20/2008 &                                                                                                                                                                                                                                                                   & Actelion Pharmaceuticals Ltd         & New Jersey & United States\\\\\n",
       "\t2 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               & 9/05/17    & 9/05/24    & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability & Actelion Pharmaceuticals Ltd         & New Jersey & United States\\\\\n",
       "\t3 & (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 & Kymriah (tisagenlecleucel) & 01/31/2014 & For the treatment of Acute Lymphoblastic Leukemia                                             & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           & 08/30/2017 & 08/30/2024 & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             & Novartis Pharmaceuticals Corporation & New Jersey & United States\\\\\n",
       "\t4 & 5-aminolevulinic acid                                                                                                                & Gleolan                    & 01/15/2013 & Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   & 6/06/17    & 6/06/24    & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     & NX Development Corporation           & Florida    & United States\\\\\n",
       "\t5 & abatacept                                                                                                                            & Orencia                    & 12/26/2017 & Prevention of graft versus host disease                                                       & prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor & 12/15/2021 &            &                                                                                                                                                                                                                                                                   & Bristol-Myers Squibb Co.             & New Jersey & United States\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 5 × 11\n",
       "\n",
       "| <!--/--> | Generic Name &lt;chr&gt; | Trade Name &lt;chr&gt; | Date Designated &lt;chr&gt; | Orphan Designation &lt;chr&gt; | Approved.Labeled.Indication &lt;chr&gt; | Marketing.Approval.Date &lt;chr&gt; | Exclusivity.End.Date &lt;chr&gt; | Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present. &lt;chr&gt; | Sponsor.Company &lt;chr&gt; | Sponsor.State &lt;chr&gt; | Sponsor.Country &lt;chr&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   | 11/20/2001 | 11/20/2008 | <!----> | Actelion Pharmaceuticals Ltd         | New Jersey | United States |\n",
       "| 2 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               | 9/05/17    | 9/05/24    | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability | Actelion Pharmaceuticals Ltd         | New Jersey | United States |\n",
       "| 3 | (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 | Kymriah (tisagenlecleucel) | 01/31/2014 | For the treatment of Acute Lymphoblastic Leukemia                                             | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           | 08/30/2017 | 08/30/2024 | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             | Novartis Pharmaceuticals Corporation | New Jersey | United States |\n",
       "| 4 | 5-aminolevulinic acid                                                                                                                | Gleolan                    | 01/15/2013 | Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   | 6/06/17    | 6/06/24    | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     | NX Development Corporation           | Florida    | United States |\n",
       "| 5 | abatacept                                                                                                                            | Orencia                    | 12/26/2017 | Prevention of graft versus host disease                                                       | prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor | 12/15/2021 | <!----> | <!----> | Bristol-Myers Squibb Co.             | New Jersey | United States |\n",
       "\n"
      ],
      "text/plain": [
       "  Generic Name                                                                                                                        \n",
       "1 bosentan                                                                                                                            \n",
       "2 bosentan                                                                                                                            \n",
       "3 (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19\n",
       "4 5-aminolevulinic acid                                                                                                               \n",
       "5 abatacept                                                                                                                           \n",
       "  Trade Name                 Date Designated\n",
       "1 Tracleer                   10/06/00       \n",
       "2 Tracleer                   10/06/00       \n",
       "3 Kymriah (tisagenlecleucel) 01/31/2014     \n",
       "4 Gleolan                    01/15/2013     \n",
       "5 Orencia                    12/26/2017     \n",
       "  Orphan Designation                                                                           \n",
       "1 Treatment of pulmonary arterial hypertension                                                 \n",
       "2 Treatment of pulmonary arterial hypertension                                                 \n",
       "3 For the treatment of Acute Lymphoblastic Leukemia                                            \n",
       "4 Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)\n",
       "5 Prevention of graft versus host disease                                                      \n",
       "  Approved.Labeled.Indication                                                                                                                                                                                                                                                                    \n",
       "1 Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              \n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  \n",
       "5 prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor\n",
       "  Marketing.Approval.Date Exclusivity.End.Date\n",
       "1 11/20/2001              11/20/2008          \n",
       "2 9/05/17                 9/05/24             \n",
       "3 08/30/2017              08/30/2024          \n",
       "4 6/06/17                 6/06/24             \n",
       "5 12/15/2021                                  \n",
       "  Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.                                                                                                                                                                       \n",
       "1                                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability\n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    \n",
       "5                                                                                                                                                                                                                                                                  \n",
       "  Sponsor.Company                      Sponsor.State Sponsor.Country\n",
       "1 Actelion Pharmaceuticals Ltd         New Jersey    United States  \n",
       "2 Actelion Pharmaceuticals Ltd         New Jersey    United States  \n",
       "3 Novartis Pharmaceuticals Corporation New Jersey    United States  \n",
       "4 NX Development Corporation           Florida       United States  \n",
       "5 Bristol-Myers Squibb Co.             New Jersey    United States  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Drop these two columns as this dataset was for approved rare disease drugs only and \n",
    "#CF Grid Key was for FDA office use only\n",
    "df <- subset(df, select = -c(Orphan.Designation.Status, CF.Grid.Key))\n",
    "\n",
    "#Drop address columns as not needed for now\n",
    "df <- subset(df, select = -c(Sponsor.Address.1, Sponsor.Address.2, Sponsor.City, Sponsor.Zip))\n",
    "head(df, 5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "f4999491",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 5 × 11</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Generic Name</th><th scope=col>Trade Name</th><th scope=col>Date Designated</th><th scope=col>Orphan Designation</th><th scope=col>Approved labelled indication</th><th scope=col>Marketing approval date</th><th scope=col>Exclusivity end date</th><th scope=col>Exclusivity protected indication</th><th scope=col>Sponsor company</th><th scope=col>Sponsor state</th><th scope=col>Sponsor country</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  </td><td>11/20/2001</td><td>11/20/2008</td><td>                                                                                                                                                                                                                                                                 </td><td>Actelion Pharmaceuticals Ltd        </td><td>New Jersey</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>2</th><td>bosentan                                                                                                                            </td><td>Tracleer                  </td><td>10/06/00  </td><td>Treatment of pulmonary arterial hypertension                                                 </td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              </td><td>9/05/17   </td><td>9/05/24   </td><td>Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability</td><td>Actelion Pharmaceuticals Ltd        </td><td>New Jersey</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>3</th><td>(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19</td><td>Kymriah (tisagenlecleucel)</td><td>01/31/2014</td><td>For the treatment of Acute Lymphoblastic Leukemia                                            </td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          </td><td>08/30/2017</td><td>08/30/2024</td><td>Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            </td><td>Novartis Pharmaceuticals Corporation</td><td>New Jersey</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>4</th><td>5-aminolevulinic acid                                                                                                               </td><td>Gleolan                   </td><td>01/15/2013</td><td>Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)</td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  </td><td>6/06/17   </td><td>6/06/24   </td><td>Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    </td><td>NX Development Corporation          </td><td>Florida   </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>5</th><td>abatacept                                                                                                                           </td><td>Orencia                   </td><td>12/26/2017</td><td>Prevention of graft versus host disease                                                      </td><td>prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor</td><td>12/15/2021</td><td>          </td><td>                                                                                                                                                                                                                                                                 </td><td>Bristol-Myers Squibb Co.            </td><td>New Jersey</td><td>United States</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 5 × 11\n",
       "\\begin{tabular}{r|lllllllllll}\n",
       "  & Generic Name & Trade Name & Date Designated & Orphan Designation & Approved labelled indication & Marketing approval date & Exclusivity end date & Exclusivity protected indication & Sponsor company & Sponsor state & Sponsor country\\\\\n",
       "  & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t1 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   & 11/20/2001 & 11/20/2008 &                                                                                                                                                                                                                                                                   & Actelion Pharmaceuticals Ltd         & New Jersey & United States\\\\\n",
       "\t2 & bosentan                                                                                                                             & Tracleer                   & 10/06/00   & Treatment of pulmonary arterial hypertension                                                  & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               & 9/05/17    & 9/05/24    & Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability & Actelion Pharmaceuticals Ltd         & New Jersey & United States\\\\\n",
       "\t3 & (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 & Kymriah (tisagenlecleucel) & 01/31/2014 & For the treatment of Acute Lymphoblastic Leukemia                                             & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           & 08/30/2017 & 08/30/2024 & Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             & Novartis Pharmaceuticals Corporation & New Jersey & United States\\\\\n",
       "\t4 & 5-aminolevulinic acid                                                                                                                & Gleolan                    & 01/15/2013 & Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   & 6/06/17    & 6/06/24    & Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     & NX Development Corporation           & Florida    & United States\\\\\n",
       "\t5 & abatacept                                                                                                                            & Orencia                    & 12/26/2017 & Prevention of graft versus host disease                                                       & prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor & 12/15/2021 &            &                                                                                                                                                                                                                                                                   & Bristol-Myers Squibb Co.             & New Jersey & United States\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 5 × 11\n",
       "\n",
       "| <!--/--> | Generic Name &lt;chr&gt; | Trade Name &lt;chr&gt; | Date Designated &lt;chr&gt; | Orphan Designation &lt;chr&gt; | Approved labelled indication &lt;chr&gt; | Marketing approval date &lt;chr&gt; | Exclusivity end date &lt;chr&gt; | Exclusivity protected indication &lt;chr&gt; | Sponsor company &lt;chr&gt; | Sponsor state &lt;chr&gt; | Sponsor country &lt;chr&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                   | 11/20/2001 | 11/20/2008 | <!----> | Actelion Pharmaceuticals Ltd         | New Jersey | United States |\n",
       "| 2 | bosentan                                                                                                                             | Tracleer                   | 10/06/00   | Treatment of pulmonary arterial hypertension                                                  | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                               | 9/05/17    | 9/05/24    | Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability | Actelion Pharmaceuticals Ltd         | New Jersey | United States |\n",
       "| 3 | (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 | Kymriah (tisagenlecleucel) | 01/31/2014 | For the treatment of Acute Lymphoblastic Leukemia                                             | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                           | 08/30/2017 | 08/30/2024 | Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                             | Novartis Pharmaceuticals Corporation | New Jersey | United States |\n",
       "| 4 | 5-aminolevulinic acid                                                                                                                | Gleolan                    | 01/15/2013 | Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV) | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                   | 6/06/17    | 6/06/24    | Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                     | NX Development Corporation           | Florida    | United States |\n",
       "| 5 | abatacept                                                                                                                            | Orencia                    | 12/26/2017 | Prevention of graft versus host disease                                                       | prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor | 12/15/2021 | <!----> | <!----> | Bristol-Myers Squibb Co.             | New Jersey | United States |\n",
       "\n"
      ],
      "text/plain": [
       "  Generic Name                                                                                                                        \n",
       "1 bosentan                                                                                                                            \n",
       "2 bosentan                                                                                                                            \n",
       "3 (tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19\n",
       "4 5-aminolevulinic acid                                                                                                               \n",
       "5 abatacept                                                                                                                           \n",
       "  Trade Name                 Date Designated\n",
       "1 Tracleer                   10/06/00       \n",
       "2 Tracleer                   10/06/00       \n",
       "3 Kymriah (tisagenlecleucel) 01/31/2014     \n",
       "4 Gleolan                    01/15/2013     \n",
       "5 Orencia                    12/26/2017     \n",
       "  Orphan Designation                                                                           \n",
       "1 Treatment of pulmonary arterial hypertension                                                 \n",
       "2 Treatment of pulmonary arterial hypertension                                                 \n",
       "3 For the treatment of Acute Lymphoblastic Leukemia                                            \n",
       "4 Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)\n",
       "5 Prevention of graft versus host disease                                                      \n",
       "  Approved labelled indication                                                                                                                                                                                                                                                                   \n",
       "1 Treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability                              \n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                                                          \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                                                  \n",
       "5 prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor\n",
       "  Marketing approval date Exclusivity end date\n",
       "1 11/20/2001              11/20/2008          \n",
       "2 9/05/17                 9/05/24             \n",
       "3 08/30/2017              08/30/2024          \n",
       "4 6/06/17                 6/06/24             \n",
       "5 12/15/2021                                  \n",
       "  Exclusivity protected indication                                                                                                                                                                                                                                 \n",
       "1                                                                                                                                                                                                                                                                  \n",
       "2 Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability\n",
       "3 Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse                                                                                                            \n",
       "4 Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery                                                    \n",
       "5                                                                                                                                                                                                                                                                  \n",
       "  Sponsor company                      Sponsor state Sponsor country\n",
       "1 Actelion Pharmaceuticals Ltd         New Jersey    United States  \n",
       "2 Actelion Pharmaceuticals Ltd         New Jersey    United States  \n",
       "3 Novartis Pharmaceuticals Corporation New Jersey    United States  \n",
       "4 NX Development Corporation           Florida       United States  \n",
       "5 Bristol-Myers Squibb Co.             New Jersey    United States  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Tidy up more column names\n",
    "colnames(df)[which(names(df) == \"Approved.Labeled.Indication\")] <- \"Approved labelled indication\"\n",
    "colnames(df)[which(names(df) == \"Marketing.Approval.Date\")] <- \"Marketing approval date\"\n",
    "colnames(df)[which(names(df) == \"Exclusivity.End.Date\")] <- \"Exclusivity end date\"\n",
    "colnames(df)[which(names(df) == \"Exclusivity.Protected.Indication....Shown.for.approvals.from.Jan..1..2013..to.the.present.\")] <- \"Exclusivity protected indication\"\n",
    "colnames(df)[which(names(df) == \"Sponsor.Company\")] <- \"Sponsor company\"\n",
    "colnames(df)[which(names(df) == \"Sponsor.State\")] <- \"Sponsor state\"\n",
    "colnames(df)[which(names(df) == \"Sponsor.Country\")] <- \"Sponsor country\"\n",
    "head(df, 5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "c24f854d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[1] 11\n",
      "[1] 1058\n"
     ]
    }
   ],
   "source": [
    "#Check numbers of columns and rows after removing some of the columns\n",
    "print(ncol(df))\n",
    "print(nrow(df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "6e017a61",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 5 × 11</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Generic Name</th><th scope=col>Trade Name</th><th scope=col>Date Designated</th><th scope=col>Orphan Designation</th><th scope=col>Approved labelled indication</th><th scope=col>Marketing approval date</th><th scope=col>Exclusivity end date</th><th scope=col>Exclusivity protected indication</th><th scope=col>Sponsor company</th><th scope=col>Sponsor state</th><th scope=col>Sponsor country</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1054</th><td>zanubrutinib                                                                                      </td><td>Brukinsa     </td><td>08/24/2020</td><td>Treatment of nodal marginal zone lymphoma</td><td>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                               </td><td>09/14/2021</td><td>09/14/2028</td><td>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen</td><td>BeiGene USA, Inc.             </td><td>California    </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1055</th><td>zidovudine                                                                                        </td><td>Retrovir     </td><td>07/17/1985</td><td>Treatment of AIDS                        </td><td>Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun</td><td>03/19/1987</td><td>03/19/1994</td><td>                                                                                                                                           </td><td>Glaxo Wellcome Inc.           </td><td>North Carolina</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1056</th><td>Zinc acetate                                                                                      </td><td>Galzin       </td><td>11/06/85  </td><td>Treatment of Wilson's disease.           </td><td>For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                       </td><td>01/28/1997</td><td>01/28/2004</td><td>                                                                                                                                           </td><td>Lemmon Company                </td><td>Pennsylvania  </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1057</th><td>Zoledronate                                                                                       </td><td>Zometa, Zabel</td><td>08/18/2000</td><td>Treatment of tumor induced hypercalcemia.</td><td>Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                 </td><td>08/20/2001</td><td>08/20/2008</td><td>                                                                                                                                           </td><td>Novartis Pharmaceuticals Corp.</td><td>New Jersey    </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1058</th><td>Note: Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.</td><td>             </td><td>          </td><td>                                         </td><td>                                                                                                                                                                                                                                                                                                          </td><td>          </td><td>          </td><td>                                                                                                                                           </td><td>                              </td><td>              </td><td>             </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 5 × 11\n",
       "\\begin{tabular}{r|lllllllllll}\n",
       "  & Generic Name & Trade Name & Date Designated & Orphan Designation & Approved labelled indication & Marketing approval date & Exclusivity end date & Exclusivity protected indication & Sponsor company & Sponsor state & Sponsor country\\\\\n",
       "  & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t1054 & zanubrutinib                                                                                       & Brukinsa      & 08/24/2020 & Treatment of nodal marginal zone lymphoma & Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                                & 09/14/2021 & 09/14/2028 & Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen & BeiGene USA, Inc.              & California     & United States\\\\\n",
       "\t1055 & zidovudine                                                                                         & Retrovir      & 07/17/1985 & Treatment of AIDS                         & Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun & 03/19/1987 & 03/19/1994 &                                                                                                                                             & Glaxo Wellcome Inc.            & North Carolina & United States\\\\\n",
       "\t1056 & Zinc acetate                                                                                       & Galzin        & 11/06/85   & Treatment of Wilson's disease.            & For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                        & 01/28/1997 & 01/28/2004 &                                                                                                                                             & Lemmon Company                 & Pennsylvania   & United States\\\\\n",
       "\t1057 & Zoledronate                                                                                        & Zometa, Zabel & 08/18/2000 & Treatment of tumor induced hypercalcemia. & Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                  & 08/20/2001 & 08/20/2008 &                                                                                                                                             & Novartis Pharmaceuticals Corp. & New Jersey     & United States\\\\\n",
       "\t1058 & Note: Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present. &               &            &                                           &                                                                                                                                                                                                                                                                                                            &            &            &                                                                                                                                             &                                &                &              \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 5 × 11\n",
       "\n",
       "| <!--/--> | Generic Name &lt;chr&gt; | Trade Name &lt;chr&gt; | Date Designated &lt;chr&gt; | Orphan Designation &lt;chr&gt; | Approved labelled indication &lt;chr&gt; | Marketing approval date &lt;chr&gt; | Exclusivity end date &lt;chr&gt; | Exclusivity protected indication &lt;chr&gt; | Sponsor company &lt;chr&gt; | Sponsor state &lt;chr&gt; | Sponsor country &lt;chr&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1054 | zanubrutinib                                                                                       | Brukinsa      | 08/24/2020 | Treatment of nodal marginal zone lymphoma | Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                                | 09/14/2021 | 09/14/2028 | Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen | BeiGene USA, Inc.              | California     | United States |\n",
       "| 1055 | zidovudine                                                                                         | Retrovir      | 07/17/1985 | Treatment of AIDS                         | Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun | 03/19/1987 | 03/19/1994 | <!----> | Glaxo Wellcome Inc.            | North Carolina | United States |\n",
       "| 1056 | Zinc acetate                                                                                       | Galzin        | 11/06/85   | Treatment of Wilson's disease.            | For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                        | 01/28/1997 | 01/28/2004 | <!----> | Lemmon Company                 | Pennsylvania   | United States |\n",
       "| 1057 | Zoledronate                                                                                        | Zometa, Zabel | 08/18/2000 | Treatment of tumor induced hypercalcemia. | Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                  | 08/20/2001 | 08/20/2008 | <!----> | Novartis Pharmaceuticals Corp. | New Jersey     | United States |\n",
       "| 1058 | Note: Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present. | <!----> | <!----> | <!----> | <!----> | <!----> | <!----> | <!----> | <!----> | <!----> | <!----> |\n",
       "\n"
      ],
      "text/plain": [
       "     Generic Name                                                                                      \n",
       "1054 zanubrutinib                                                                                      \n",
       "1055 zidovudine                                                                                        \n",
       "1056 Zinc acetate                                                                                      \n",
       "1057 Zoledronate                                                                                       \n",
       "1058 Note: Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.\n",
       "     Trade Name    Date Designated Orphan Designation                       \n",
       "1054 Brukinsa      08/24/2020      Treatment of nodal marginal zone lymphoma\n",
       "1055 Retrovir      07/17/1985      Treatment of AIDS                        \n",
       "1056 Galzin        11/06/85        Treatment of Wilson's disease.           \n",
       "1057 Zometa, Zabel 08/18/2000      Treatment of tumor induced hypercalcemia.\n",
       "1058                                                                        \n",
       "     Approved labelled indication                                                                                                                                                                                                                                                                              \n",
       "1054 Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                               \n",
       "1055 Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun\n",
       "1056 For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                       \n",
       "1057 Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                 \n",
       "1058                                                                                                                                                                                                                                                                                                           \n",
       "     Marketing approval date Exclusivity end date\n",
       "1054 09/14/2021              09/14/2028          \n",
       "1055 03/19/1987              03/19/1994          \n",
       "1056 01/28/1997              01/28/2004          \n",
       "1057 08/20/2001              08/20/2008          \n",
       "1058                                             \n",
       "     Exclusivity protected indication                                                                                                           \n",
       "1054 Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen\n",
       "1055                                                                                                                                            \n",
       "1056                                                                                                                                            \n",
       "1057                                                                                                                                            \n",
       "1058                                                                                                                                            \n",
       "     Sponsor company                Sponsor state  Sponsor country\n",
       "1054 BeiGene USA, Inc.              California     United States  \n",
       "1055 Glaxo Wellcome Inc.            North Carolina United States  \n",
       "1056 Lemmon Company                 Pennsylvania   United States  \n",
       "1057 Novartis Pharmaceuticals Corp. New Jersey     United States  \n",
       "1058                                                              "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Show last five rows of the dataframe\n",
    "tail(df, 5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "33c79dd2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 5 × 11</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Generic Name</th><th scope=col>Trade Name</th><th scope=col>Date Designated</th><th scope=col>Orphan Designation</th><th scope=col>Approved labelled indication</th><th scope=col>Marketing approval date</th><th scope=col>Exclusivity end date</th><th scope=col>Exclusivity protected indication</th><th scope=col>Sponsor company</th><th scope=col>Sponsor state</th><th scope=col>Sponsor country</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1053</th><td>zanubrutinib</td><td>Brukinsa     </td><td>08/24/2020</td><td>Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue</td><td>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                               </td><td>09/14/2021</td><td>09/14/2028</td><td>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen</td><td>BeiGene USA, Inc.             </td><td>California    </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1054</th><td>zanubrutinib</td><td>Brukinsa     </td><td>08/24/2020</td><td>Treatment of nodal marginal zone lymphoma                                          </td><td>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                               </td><td>09/14/2021</td><td>09/14/2028</td><td>Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen</td><td>BeiGene USA, Inc.             </td><td>California    </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1055</th><td>zidovudine  </td><td>Retrovir     </td><td>07/17/1985</td><td>Treatment of AIDS                                                                  </td><td>Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun</td><td>03/19/1987</td><td>03/19/1994</td><td>                                                                                                                                           </td><td>Glaxo Wellcome Inc.           </td><td>North Carolina</td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1056</th><td>Zinc acetate</td><td>Galzin       </td><td>11/06/85  </td><td>Treatment of Wilson's disease.                                                     </td><td>For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                       </td><td>01/28/1997</td><td>01/28/2004</td><td>                                                                                                                                           </td><td>Lemmon Company                </td><td>Pennsylvania  </td><td>United States</td></tr>\n",
       "\t<tr><th scope=row>1057</th><td>Zoledronate </td><td>Zometa, Zabel</td><td>08/18/2000</td><td>Treatment of tumor induced hypercalcemia.                                          </td><td>Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                 </td><td>08/20/2001</td><td>08/20/2008</td><td>                                                                                                                                           </td><td>Novartis Pharmaceuticals Corp.</td><td>New Jersey    </td><td>United States</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 5 × 11\n",
       "\\begin{tabular}{r|lllllllllll}\n",
       "  & Generic Name & Trade Name & Date Designated & Orphan Designation & Approved labelled indication & Marketing approval date & Exclusivity end date & Exclusivity protected indication & Sponsor company & Sponsor state & Sponsor country\\\\\n",
       "  & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t1053 & zanubrutinib & Brukinsa      & 08/24/2020 & Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue & Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                                & 09/14/2021 & 09/14/2028 & Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen & BeiGene USA, Inc.              & California     & United States\\\\\n",
       "\t1054 & zanubrutinib & Brukinsa      & 08/24/2020 & Treatment of nodal marginal zone lymphoma                                           & Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                                & 09/14/2021 & 09/14/2028 & Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen & BeiGene USA, Inc.              & California     & United States\\\\\n",
       "\t1055 & zidovudine   & Retrovir      & 07/17/1985 & Treatment of AIDS                                                                   & Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun & 03/19/1987 & 03/19/1994 &                                                                                                                                             & Glaxo Wellcome Inc.            & North Carolina & United States\\\\\n",
       "\t1056 & Zinc acetate & Galzin        & 11/06/85   & Treatment of Wilson's disease.                                                      & For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                        & 01/28/1997 & 01/28/2004 &                                                                                                                                             & Lemmon Company                 & Pennsylvania   & United States\\\\\n",
       "\t1057 & Zoledronate  & Zometa, Zabel & 08/18/2000 & Treatment of tumor induced hypercalcemia.                                           & Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                  & 08/20/2001 & 08/20/2008 &                                                                                                                                             & Novartis Pharmaceuticals Corp. & New Jersey     & United States\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 5 × 11\n",
       "\n",
       "| <!--/--> | Generic Name &lt;chr&gt; | Trade Name &lt;chr&gt; | Date Designated &lt;chr&gt; | Orphan Designation &lt;chr&gt; | Approved labelled indication &lt;chr&gt; | Marketing approval date &lt;chr&gt; | Exclusivity end date &lt;chr&gt; | Exclusivity protected indication &lt;chr&gt; | Sponsor company &lt;chr&gt; | Sponsor state &lt;chr&gt; | Sponsor country &lt;chr&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| 1053 | zanubrutinib | Brukinsa      | 08/24/2020 | Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                                | 09/14/2021 | 09/14/2028 | Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen | BeiGene USA, Inc.              | California     | United States |\n",
       "| 1054 | zanubrutinib | Brukinsa      | 08/24/2020 | Treatment of nodal marginal zone lymphoma                                           | Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                                | 09/14/2021 | 09/14/2028 | Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen | BeiGene USA, Inc.              | California     | United States |\n",
       "| 1055 | zidovudine   | Retrovir      | 07/17/1985 | Treatment of AIDS                                                                   | Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun | 03/19/1987 | 03/19/1994 | <!----> | Glaxo Wellcome Inc.            | North Carolina | United States |\n",
       "| 1056 | Zinc acetate | Galzin        | 11/06/85   | Treatment of Wilson's disease.                                                      | For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                        | 01/28/1997 | 01/28/2004 | <!----> | Lemmon Company                 | Pennsylvania   | United States |\n",
       "| 1057 | Zoledronate  | Zometa, Zabel | 08/18/2000 | Treatment of tumor induced hypercalcemia.                                           | Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                  | 08/20/2001 | 08/20/2008 | <!----> | Novartis Pharmaceuticals Corp. | New Jersey     | United States |\n",
       "\n"
      ],
      "text/plain": [
       "     Generic Name Trade Name    Date Designated\n",
       "1053 zanubrutinib Brukinsa      08/24/2020     \n",
       "1054 zanubrutinib Brukinsa      08/24/2020     \n",
       "1055 zidovudine   Retrovir      07/17/1985     \n",
       "1056 Zinc acetate Galzin        11/06/85       \n",
       "1057 Zoledronate  Zometa, Zabel 08/18/2000     \n",
       "     Orphan Designation                                                                 \n",
       "1053 Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue\n",
       "1054 Treatment of nodal marginal zone lymphoma                                          \n",
       "1055 Treatment of AIDS                                                                  \n",
       "1056 Treatment of Wilson's disease.                                                     \n",
       "1057 Treatment of tumor induced hypercalcemia.                                          \n",
       "     Approved labelled indication                                                                                                                                                                                                                                                                              \n",
       "1053 Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                               \n",
       "1054 Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen                                                                                                                                                               \n",
       "1055 Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun\n",
       "1056 For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.                                                                                                                                                                                       \n",
       "1057 Treatment of hypercalcemia of malignancy.                                                                                                                                                                                                                                                                 \n",
       "     Marketing approval date Exclusivity end date\n",
       "1053 09/14/2021              09/14/2028          \n",
       "1054 09/14/2021              09/14/2028          \n",
       "1055 03/19/1987              03/19/1994          \n",
       "1056 01/28/1997              01/28/2004          \n",
       "1057 08/20/2001              08/20/2008          \n",
       "     Exclusivity protected indication                                                                                                           \n",
       "1053 Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen\n",
       "1054 Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen\n",
       "1055                                                                                                                                            \n",
       "1056                                                                                                                                            \n",
       "1057                                                                                                                                            \n",
       "     Sponsor company                Sponsor state  Sponsor country\n",
       "1053 BeiGene USA, Inc.              California     United States  \n",
       "1054 BeiGene USA, Inc.              California     United States  \n",
       "1055 Glaxo Wellcome Inc.            North Carolina United States  \n",
       "1056 Lemmon Company                 Pennsylvania   United States  \n",
       "1057 Novartis Pharmaceuticals Corp. New Jersey     United States  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Remove row number 1058 as this was only an explanatory caption for exclusivity protected indication\n",
    "df <- df[-c(1058), ]\n",
    "tail(df, 5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "be0fe782",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 21 × 1</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Sponsor country</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>United States </td></tr>\n",
       "\t<tr><th scope=row>33</th><td>Barbados      </td></tr>\n",
       "\t<tr><th scope=row>35</th><td>Switzerland   </td></tr>\n",
       "\t<tr><th scope=row>49</th><td>Sweden        </td></tr>\n",
       "\t<tr><th scope=row>52</th><td>Canada        </td></tr>\n",
       "\t<tr><th scope=row>77</th><td>Ireland       </td></tr>\n",
       "\t<tr><th scope=row>109</th><td>United Kingdom</td></tr>\n",
       "\t<tr><th scope=row>118</th><td>Spain         </td></tr>\n",
       "\t<tr><th scope=row>124</th><td>France        </td></tr>\n",
       "\t<tr><th scope=row>171</th><td>Netherlands   </td></tr>\n",
       "\t<tr><th scope=row>179</th><td>Japan         </td></tr>\n",
       "\t<tr><th scope=row>216</th><td>Italy         </td></tr>\n",
       "\t<tr><th scope=row>323</th><td>Israel        </td></tr>\n",
       "\t<tr><th scope=row>330</th><td>Germany       </td></tr>\n",
       "\t<tr><th scope=row>351</th><td>Belgium       </td></tr>\n",
       "\t<tr><th scope=row>542</th><td>Austria       </td></tr>\n",
       "\t<tr><th scope=row>589</th><td>Denmark       </td></tr>\n",
       "\t<tr><th scope=row>654</th><td>Australia     </td></tr>\n",
       "\t<tr><th scope=row>858</th><td>Taiwan        </td></tr>\n",
       "\t<tr><th scope=row>902</th><td>Malta         </td></tr>\n",
       "\t<tr><th scope=row>995</th><td>Finland       </td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 21 × 1\n",
       "\\begin{tabular}{r|l}\n",
       "  & Sponsor country\\\\\n",
       "  & <chr>\\\\\n",
       "\\hline\n",
       "\t1 & United States \\\\\n",
       "\t33 & Barbados      \\\\\n",
       "\t35 & Switzerland   \\\\\n",
       "\t49 & Sweden        \\\\\n",
       "\t52 & Canada        \\\\\n",
       "\t77 & Ireland       \\\\\n",
       "\t109 & United Kingdom\\\\\n",
       "\t118 & Spain         \\\\\n",
       "\t124 & France        \\\\\n",
       "\t171 & Netherlands   \\\\\n",
       "\t179 & Japan         \\\\\n",
       "\t216 & Italy         \\\\\n",
       "\t323 & Israel        \\\\\n",
       "\t330 & Germany       \\\\\n",
       "\t351 & Belgium       \\\\\n",
       "\t542 & Austria       \\\\\n",
       "\t589 & Denmark       \\\\\n",
       "\t654 & Australia     \\\\\n",
       "\t858 & Taiwan        \\\\\n",
       "\t902 & Malta         \\\\\n",
       "\t995 & Finland       \\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 21 × 1\n",
       "\n",
       "| <!--/--> | Sponsor country &lt;chr&gt; |\n",
       "|---|---|\n",
       "| 1 | United States  |\n",
       "| 33 | Barbados       |\n",
       "| 35 | Switzerland    |\n",
       "| 49 | Sweden         |\n",
       "| 52 | Canada         |\n",
       "| 77 | Ireland        |\n",
       "| 109 | United Kingdom |\n",
       "| 118 | Spain          |\n",
       "| 124 | France         |\n",
       "| 171 | Netherlands    |\n",
       "| 179 | Japan          |\n",
       "| 216 | Italy          |\n",
       "| 323 | Israel         |\n",
       "| 330 | Germany        |\n",
       "| 351 | Belgium        |\n",
       "| 542 | Austria        |\n",
       "| 589 | Denmark        |\n",
       "| 654 | Australia      |\n",
       "| 858 | Taiwan         |\n",
       "| 902 | Malta          |\n",
       "| 995 | Finland        |\n",
       "\n"
      ],
      "text/plain": [
       "    Sponsor country\n",
       "1   United States  \n",
       "33  Barbados       \n",
       "35  Switzerland    \n",
       "49  Sweden         \n",
       "52  Canada         \n",
       "77  Ireland        \n",
       "109 United Kingdom \n",
       "118 Spain          \n",
       "124 France         \n",
       "171 Netherlands    \n",
       "179 Japan          \n",
       "216 Italy          \n",
       "323 Israel         \n",
       "330 Germany        \n",
       "351 Belgium        \n",
       "542 Austria        \n",
       "589 Denmark        \n",
       "654 Australia      \n",
       "858 Taiwan         \n",
       "902 Malta          \n",
       "995 Finland        "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Check countries involved in developing rare disease drugs \n",
    "unique(df[\"Sponsor country\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "4f3c670c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\n",
       "     Australia        Austria       Barbados        Belgium         Canada \n",
       "             1              1              1              2              8 \n",
       "       Denmark        Finland         France        Germany        Ireland \n",
       "             1              1             10              4             16 \n",
       "        Israel          Italy          Japan          Malta    Netherlands \n",
       "             2              3              5              1              3 \n",
       "         Spain         Sweden    Switzerland         Taiwan United Kingdom \n",
       "             1              8              9              1             13 \n",
       " United States \n",
       "           966 "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Find out the frequencies of countries involved in developing rare disease drugs\n",
    "table1 = table(df$\"Sponsor country\")\n",
    "table1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "2a1fdc30",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 1 × 21</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Australia</th><th scope=col>Austria</th><th scope=col>Barbados</th><th scope=col>Belgium</th><th scope=col>Canada</th><th scope=col>Denmark</th><th scope=col>Finland</th><th scope=col>France</th><th scope=col>Germany</th><th scope=col>Ireland</th><th scope=col>⋯</th><th scope=col>Italy</th><th scope=col>Japan</th><th scope=col>Malta</th><th scope=col>Netherlands</th><th scope=col>Spain</th><th scope=col>Sweden</th><th scope=col>Switzerland</th><th scope=col>Taiwan</th><th scope=col>United.Kingdom</th><th scope=col>United.States</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>⋯</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;int&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>table1</th><td>1</td><td>1</td><td>1</td><td>2</td><td>8</td><td>1</td><td>1</td><td>10</td><td>4</td><td>16</td><td>⋯</td><td>3</td><td>5</td><td>1</td><td>3</td><td>1</td><td>8</td><td>9</td><td>1</td><td>13</td><td>966</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 1 × 21\n",
       "\\begin{tabular}{r|lllllllllllllllllllll}\n",
       "  & Australia & Austria & Barbados & Belgium & Canada & Denmark & Finland & France & Germany & Ireland & ⋯ & Italy & Japan & Malta & Netherlands & Spain & Sweden & Switzerland & Taiwan & United.Kingdom & United.States\\\\\n",
       "  & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & ⋯ & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int> & <int>\\\\\n",
       "\\hline\n",
       "\ttable1 & 1 & 1 & 1 & 2 & 8 & 1 & 1 & 10 & 4 & 16 & ⋯ & 3 & 5 & 1 & 3 & 1 & 8 & 9 & 1 & 13 & 966\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 1 × 21\n",
       "\n",
       "| <!--/--> | Australia &lt;int&gt; | Austria &lt;int&gt; | Barbados &lt;int&gt; | Belgium &lt;int&gt; | Canada &lt;int&gt; | Denmark &lt;int&gt; | Finland &lt;int&gt; | France &lt;int&gt; | Germany &lt;int&gt; | Ireland &lt;int&gt; | ⋯ ⋯ | Italy &lt;int&gt; | Japan &lt;int&gt; | Malta &lt;int&gt; | Netherlands &lt;int&gt; | Spain &lt;int&gt; | Sweden &lt;int&gt; | Switzerland &lt;int&gt; | Taiwan &lt;int&gt; | United.Kingdom &lt;int&gt; | United.States &lt;int&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| table1 | 1 | 1 | 1 | 2 | 8 | 1 | 1 | 10 | 4 | 16 | ⋯ | 3 | 5 | 1 | 3 | 1 | 8 | 9 | 1 | 13 | 966 |\n",
       "\n"
      ],
      "text/plain": [
       "       Australia Austria Barbados Belgium Canada Denmark Finland France Germany\n",
       "table1 1         1       1        2       8      1       1       10     4      \n",
       "       Ireland ⋯ Italy Japan Malta Netherlands Spain Sweden Switzerland Taiwan\n",
       "table1 16      ⋯ 3     5     1     3           1     8      9           1     \n",
       "       United.Kingdom United.States\n",
       "table1 13             966          "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Convert above table into a new dataframe\n",
    "new_df <- data.frame(rbind(table1))\n",
    "new_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "0e938eef",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A matrix: 21 × 1 of type int</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>table1</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>Australia</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>Austria</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>Barbados</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>Belgium</th><td>  2</td></tr>\n",
       "\t<tr><th scope=row>Canada</th><td>  8</td></tr>\n",
       "\t<tr><th scope=row>Denmark</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>Finland</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>France</th><td> 10</td></tr>\n",
       "\t<tr><th scope=row>Germany</th><td>  4</td></tr>\n",
       "\t<tr><th scope=row>Ireland</th><td> 16</td></tr>\n",
       "\t<tr><th scope=row>Israel</th><td>  2</td></tr>\n",
       "\t<tr><th scope=row>Italy</th><td>  3</td></tr>\n",
       "\t<tr><th scope=row>Japan</th><td>  5</td></tr>\n",
       "\t<tr><th scope=row>Malta</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>Netherlands</th><td>  3</td></tr>\n",
       "\t<tr><th scope=row>Spain</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>Sweden</th><td>  8</td></tr>\n",
       "\t<tr><th scope=row>Switzerland</th><td>  9</td></tr>\n",
       "\t<tr><th scope=row>Taiwan</th><td>  1</td></tr>\n",
       "\t<tr><th scope=row>United.Kingdom</th><td> 13</td></tr>\n",
       "\t<tr><th scope=row>United.States</th><td>966</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A matrix: 21 × 1 of type int\n",
       "\\begin{tabular}{r|l}\n",
       "  & table1\\\\\n",
       "\\hline\n",
       "\tAustralia &   1\\\\\n",
       "\tAustria &   1\\\\\n",
       "\tBarbados &   1\\\\\n",
       "\tBelgium &   2\\\\\n",
       "\tCanada &   8\\\\\n",
       "\tDenmark &   1\\\\\n",
       "\tFinland &   1\\\\\n",
       "\tFrance &  10\\\\\n",
       "\tGermany &   4\\\\\n",
       "\tIreland &  16\\\\\n",
       "\tIsrael &   2\\\\\n",
       "\tItaly &   3\\\\\n",
       "\tJapan &   5\\\\\n",
       "\tMalta &   1\\\\\n",
       "\tNetherlands &   3\\\\\n",
       "\tSpain &   1\\\\\n",
       "\tSweden &   8\\\\\n",
       "\tSwitzerland &   9\\\\\n",
       "\tTaiwan &   1\\\\\n",
       "\tUnited.Kingdom &  13\\\\\n",
       "\tUnited.States & 966\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A matrix: 21 × 1 of type int\n",
       "\n",
       "| <!--/--> | table1 |\n",
       "|---|---|\n",
       "| Australia |   1 |\n",
       "| Austria |   1 |\n",
       "| Barbados |   1 |\n",
       "| Belgium |   2 |\n",
       "| Canada |   8 |\n",
       "| Denmark |   1 |\n",
       "| Finland |   1 |\n",
       "| France |  10 |\n",
       "| Germany |   4 |\n",
       "| Ireland |  16 |\n",
       "| Israel |   2 |\n",
       "| Italy |   3 |\n",
       "| Japan |   5 |\n",
       "| Malta |   1 |\n",
       "| Netherlands |   3 |\n",
       "| Spain |   1 |\n",
       "| Sweden |   8 |\n",
       "| Switzerland |   9 |\n",
       "| Taiwan |   1 |\n",
       "| United.Kingdom |  13 |\n",
       "| United.States | 966 |\n",
       "\n"
      ],
      "text/plain": [
       "               table1\n",
       "Australia        1   \n",
       "Austria          1   \n",
       "Barbados         1   \n",
       "Belgium          2   \n",
       "Canada           8   \n",
       "Denmark          1   \n",
       "Finland          1   \n",
       "France          10   \n",
       "Germany          4   \n",
       "Ireland         16   \n",
       "Israel           2   \n",
       "Italy            3   \n",
       "Japan            5   \n",
       "Malta            1   \n",
       "Netherlands      3   \n",
       "Spain            1   \n",
       "Sweden           8   \n",
       "Switzerland      9   \n",
       "Taiwan           1   \n",
       "United.Kingdom  13   \n",
       "United.States  966   "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Transpose the column and row to make it easier to read\n",
    "df_transpose = t(new_df)\n",
    "df_transpose"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "744abeea",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A matrix: 21 × 2 of type chr</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Country</th><th scope=col>Frequency</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>Australia     </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>2</th><td>Austria       </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>3</th><td>Barbados      </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>4</th><td>Belgium       </td><td>2  </td></tr>\n",
       "\t<tr><th scope=row>5</th><td>Canada        </td><td>8  </td></tr>\n",
       "\t<tr><th scope=row>6</th><td>Denmark       </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>7</th><td>Finland       </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>8</th><td>France        </td><td>10 </td></tr>\n",
       "\t<tr><th scope=row>9</th><td>Germany       </td><td>4  </td></tr>\n",
       "\t<tr><th scope=row>10</th><td>Ireland       </td><td>16 </td></tr>\n",
       "\t<tr><th scope=row>11</th><td>Israel        </td><td>2  </td></tr>\n",
       "\t<tr><th scope=row>12</th><td>Italy         </td><td>3  </td></tr>\n",
       "\t<tr><th scope=row>13</th><td>Japan         </td><td>5  </td></tr>\n",
       "\t<tr><th scope=row>14</th><td>Malta         </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>15</th><td>Netherlands   </td><td>3  </td></tr>\n",
       "\t<tr><th scope=row>16</th><td>Spain         </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>17</th><td>Sweden        </td><td>8  </td></tr>\n",
       "\t<tr><th scope=row>18</th><td>Switzerland   </td><td>9  </td></tr>\n",
       "\t<tr><th scope=row>19</th><td>Taiwan        </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>20</th><td>United.Kingdom</td><td>13 </td></tr>\n",
       "\t<tr><th scope=row>21</th><td>United.States </td><td>966</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A matrix: 21 × 2 of type chr\n",
       "\\begin{tabular}{r|ll}\n",
       "  & Country & Frequency\\\\\n",
       "\\hline\n",
       "\t1 & Australia      & 1  \\\\\n",
       "\t2 & Austria        & 1  \\\\\n",
       "\t3 & Barbados       & 1  \\\\\n",
       "\t4 & Belgium        & 2  \\\\\n",
       "\t5 & Canada         & 8  \\\\\n",
       "\t6 & Denmark        & 1  \\\\\n",
       "\t7 & Finland        & 1  \\\\\n",
       "\t8 & France         & 10 \\\\\n",
       "\t9 & Germany        & 4  \\\\\n",
       "\t10 & Ireland        & 16 \\\\\n",
       "\t11 & Israel         & 2  \\\\\n",
       "\t12 & Italy          & 3  \\\\\n",
       "\t13 & Japan          & 5  \\\\\n",
       "\t14 & Malta          & 1  \\\\\n",
       "\t15 & Netherlands    & 3  \\\\\n",
       "\t16 & Spain          & 1  \\\\\n",
       "\t17 & Sweden         & 8  \\\\\n",
       "\t18 & Switzerland    & 9  \\\\\n",
       "\t19 & Taiwan         & 1  \\\\\n",
       "\t20 & United.Kingdom & 13 \\\\\n",
       "\t21 & United.States  & 966\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A matrix: 21 × 2 of type chr\n",
       "\n",
       "| <!--/--> | Country | Frequency |\n",
       "|---|---|---|\n",
       "| 1 | Australia      | 1   |\n",
       "| 2 | Austria        | 1   |\n",
       "| 3 | Barbados       | 1   |\n",
       "| 4 | Belgium        | 2   |\n",
       "| 5 | Canada         | 8   |\n",
       "| 6 | Denmark        | 1   |\n",
       "| 7 | Finland        | 1   |\n",
       "| 8 | France         | 10  |\n",
       "| 9 | Germany        | 4   |\n",
       "| 10 | Ireland        | 16  |\n",
       "| 11 | Israel         | 2   |\n",
       "| 12 | Italy          | 3   |\n",
       "| 13 | Japan          | 5   |\n",
       "| 14 | Malta          | 1   |\n",
       "| 15 | Netherlands    | 3   |\n",
       "| 16 | Spain          | 1   |\n",
       "| 17 | Sweden         | 8   |\n",
       "| 18 | Switzerland    | 9   |\n",
       "| 19 | Taiwan         | 1   |\n",
       "| 20 | United.Kingdom | 13  |\n",
       "| 21 | United.States  | 966 |\n",
       "\n"
      ],
      "text/plain": [
       "   Country        Frequency\n",
       "1  Australia      1        \n",
       "2  Austria        1        \n",
       "3  Barbados       1        \n",
       "4  Belgium        2        \n",
       "5  Canada         8        \n",
       "6  Denmark        1        \n",
       "7  Finland        1        \n",
       "8  France         10       \n",
       "9  Germany        4        \n",
       "10 Ireland        16       \n",
       "11 Israel         2        \n",
       "12 Italy          3        \n",
       "13 Japan          5        \n",
       "14 Malta          1        \n",
       "15 Netherlands    3        \n",
       "16 Spain          1        \n",
       "17 Sweden         8        \n",
       "18 Switzerland    9        \n",
       "19 Taiwan         1        \n",
       "20 United.Kingdom 13       \n",
       "21 United.States  966      "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Add column name for frequency counts\n",
    "colnames(df_transpose) <- c('Frequency')\n",
    "#Add column name for the countries listed\n",
    "df_transpose <- cbind(Country = rownames(df_transpose), df_transpose)\n",
    "#Add index to rows \n",
    "rownames(df_transpose) <- 1:nrow(df_transpose)\n",
    "\n",
    "df_transpose"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "e472bb05",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A data.frame: 21 × 2</caption>\n",
       "<thead>\n",
       "\t<tr><th></th><th scope=col>Country</th><th scope=col>Frequency</th></tr>\n",
       "\t<tr><th></th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><th scope=row>1</th><td>Australia     </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>2</th><td>Austria       </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>3</th><td>Barbados      </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>4</th><td>Belgium       </td><td>2  </td></tr>\n",
       "\t<tr><th scope=row>5</th><td>Canada        </td><td>8  </td></tr>\n",
       "\t<tr><th scope=row>6</th><td>Denmark       </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>7</th><td>Finland       </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>8</th><td>France        </td><td>10 </td></tr>\n",
       "\t<tr><th scope=row>9</th><td>Germany       </td><td>4  </td></tr>\n",
       "\t<tr><th scope=row>10</th><td>Ireland       </td><td>16 </td></tr>\n",
       "\t<tr><th scope=row>11</th><td>Israel        </td><td>2  </td></tr>\n",
       "\t<tr><th scope=row>12</th><td>Italy         </td><td>3  </td></tr>\n",
       "\t<tr><th scope=row>13</th><td>Japan         </td><td>5  </td></tr>\n",
       "\t<tr><th scope=row>14</th><td>Malta         </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>15</th><td>Netherlands   </td><td>3  </td></tr>\n",
       "\t<tr><th scope=row>16</th><td>Spain         </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>17</th><td>Sweden        </td><td>8  </td></tr>\n",
       "\t<tr><th scope=row>18</th><td>Switzerland   </td><td>9  </td></tr>\n",
       "\t<tr><th scope=row>19</th><td>Taiwan        </td><td>1  </td></tr>\n",
       "\t<tr><th scope=row>20</th><td>United.Kingdom</td><td>13 </td></tr>\n",
       "\t<tr><th scope=row>21</th><td>United.States </td><td>966</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A data.frame: 21 × 2\n",
       "\\begin{tabular}{r|ll}\n",
       "  & Country & Frequency\\\\\n",
       "  & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t1 & Australia      & 1  \\\\\n",
       "\t2 & Austria        & 1  \\\\\n",
       "\t3 & Barbados       & 1  \\\\\n",
       "\t4 & Belgium        & 2  \\\\\n",
       "\t5 & Canada         & 8  \\\\\n",
       "\t6 & Denmark        & 1  \\\\\n",
       "\t7 & Finland        & 1  \\\\\n",
       "\t8 & France         & 10 \\\\\n",
       "\t9 & Germany        & 4  \\\\\n",
       "\t10 & Ireland        & 16 \\\\\n",
       "\t11 & Israel         & 2  \\\\\n",
       "\t12 & Italy          & 3  \\\\\n",
       "\t13 & Japan          & 5  \\\\\n",
       "\t14 & Malta          & 1  \\\\\n",
       "\t15 & Netherlands    & 3  \\\\\n",
       "\t16 & Spain          & 1  \\\\\n",
       "\t17 & Sweden         & 8  \\\\\n",
       "\t18 & Switzerland    & 9  \\\\\n",
       "\t19 & Taiwan         & 1  \\\\\n",
       "\t20 & United.Kingdom & 13 \\\\\n",
       "\t21 & United.States  & 966\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A data.frame: 21 × 2\n",
       "\n",
       "| <!--/--> | Country &lt;chr&gt; | Frequency &lt;chr&gt; |\n",
       "|---|---|---|\n",
       "| 1 | Australia      | 1   |\n",
       "| 2 | Austria        | 1   |\n",
       "| 3 | Barbados       | 1   |\n",
       "| 4 | Belgium        | 2   |\n",
       "| 5 | Canada         | 8   |\n",
       "| 6 | Denmark        | 1   |\n",
       "| 7 | Finland        | 1   |\n",
       "| 8 | France         | 10  |\n",
       "| 9 | Germany        | 4   |\n",
       "| 10 | Ireland        | 16  |\n",
       "| 11 | Israel         | 2   |\n",
       "| 12 | Italy          | 3   |\n",
       "| 13 | Japan          | 5   |\n",
       "| 14 | Malta          | 1   |\n",
       "| 15 | Netherlands    | 3   |\n",
       "| 16 | Spain          | 1   |\n",
       "| 17 | Sweden         | 8   |\n",
       "| 18 | Switzerland    | 9   |\n",
       "| 19 | Taiwan         | 1   |\n",
       "| 20 | United.Kingdom | 13  |\n",
       "| 21 | United.States  | 966 |\n",
       "\n"
      ],
      "text/plain": [
       "   Country        Frequency\n",
       "1  Australia      1        \n",
       "2  Austria        1        \n",
       "3  Barbados       1        \n",
       "4  Belgium        2        \n",
       "5  Canada         8        \n",
       "6  Denmark        1        \n",
       "7  Finland        1        \n",
       "8  France         10       \n",
       "9  Germany        4        \n",
       "10 Ireland        16       \n",
       "11 Israel         2        \n",
       "12 Italy          3        \n",
       "13 Japan          5        \n",
       "14 Malta          1        \n",
       "15 Netherlands    3        \n",
       "16 Spain          1        \n",
       "17 Sweden         8        \n",
       "18 Switzerland    9        \n",
       "19 Taiwan         1        \n",
       "20 United.Kingdom 13       \n",
       "21 United.States  966      "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Change above matrix into a dataframe\n",
    "df_new = as.data.frame.matrix(df_transpose)\n",
    "df_new"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "d1bdb8a9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABLAAAASwCAYAAADrIbPPAAAEGWlDQ1BrQ0dDb2xvclNwYWNl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\nAAAASUVORK5CYII=",
      "text/plain": [
       "plot without title"
      ]
     },
     "metadata": {
      "image/png": {
       "height": 600,
       "width": 600
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Plot horizontal bar graph for all the countries involved in rare disease drug development by using above dataframe\n",
    "library(ggplot2)\n",
    "#Adjust size of the bar graph\n",
    "options(repr.plot.width = 10, repr.plot.height = 10)\n",
    "#Plot using ggplot\n",
    "ggplot(df_new, aes(x = Country, y = Frequency)) + \n",
    "geom_bar(stat = \"identity\") +\n",
    "#Change to horizontal bar graph\n",
    "coord_flip()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "51903e2d",
   "metadata": {},
   "source": [
    "From the above horizontal graph, United States, Switzerland, Canada and Sweden were the top 3 countries involved in rare disease drug development (Canada and Sweden both took the third place together).\n",
    "\n",
    "*Please see another file with the name: Rare_diseases_drugs_RStudio.md in my GitHub portfolio-projects repository for more explorations in this same data set. This work was done using RStudio along with tidyverse and a few other packages, which would be slightly more interesting than this one."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "R",
   "language": "R",
   "name": "ir"
  },
  "language_info": {
   "codemirror_mode": "r",
   "file_extension": ".r",
   "mimetype": "text/x-r-source",
   "name": "R",
   "pygments_lexer": "r",
   "version": "4.2.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
